MedPath

Pilot study for the evaluation of [68Ga]Ga-PentixaFor PET imaging for the identification of unilateral adrenal secretion of ALdosterON in patients with primary aldosteronism.

Phase 1
Conditions
Primary aldosteronism, Primary aldosteronism
MedDRA version: 20.1Level: PTClassification code: 10036692Term: Primary hyperaldosteronism Class: 100000004860
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Registration Number
CTIS2023-505507-22-00
Lead Sponsor
Assistance Publique Hopitaux De Paris
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Age = 18 years old, Signed written informed consent, French Social Security affiliation, For child-bearing aged women, efficient contraception, Diagnosis of primary aldosteronism: -With or without adrenal nodule on morphological imaging (CT or Magnetic Resonance Imaging) -With unilateral or bilateral aldosterone secretion confirmed by invasive AVS

Exclusion Criteria

Pregnant or breastfeeding women, Patient under legal protection (guardianship), Contraindication to the PET-CT, Contraindication to the injection of [68Ga]Ga-PentixaFor, Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable, Patient on AME (state medical aid) (unless exemption from affiliation), Completed group: if the expected number of patients has been reached (15 patients) in the corresponding group of patients (with lateralized or non-lateralized PA).

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath